PepGen Inc (PEPG) Stock Forecast & Price Target

PepGen is viewed favorably because PGN-EDODM1’s 10mg/kg FREEDOM-2 data showed mean splicing correction of -46.5% after four months, a 3.9-second improvement in vHOT, and more consistent patient-level responses than the 5mg/kg cohort. The safety profile also looks manageable, with four mild renal adverse events and transient albuminuria but no eGFR decline or cumulative toxicity, which supports a favorable risk/benefit case versus earlier PGN-EDO51 results. By introducing FY34 estimates, lowering the discount rate to 25%, and noting broader tissue delivery across muscle and CNS with potential differentiation in DM1, the analysis supports continued Outperform conviction.

PepGen is a clinical-stage biotech with a promising platform, but the fundamental case is weakened by substantial regulatory uncertainty, as approval may require additional data, longer studies, or labels that fail to provide meaningful differentiation in the market. Its commercial outlook is also fragile because the company has not yet proven it can execute effectively, and any inability to meet expectations could weigh on shares while competitors in these disease areas continue to expand. Financially, the company likely needs additional external funding to advance its development platform, and limited access to capital markets could delay or even terminate development campaigns.